PG545 (pixatimod) in combination with nivolumab

Program Status

Recruiting

Phase

Phase 1

Prior Immunotherapy Allowed

Yes

CRC-directed Trial

Yes

Tags

MSI-H/ MMRd, MSS/ MMRp

Comments

Trial with preliminar good result in CRC, only in Australia.
Nov 2018: “Of the 5 subjects evaluable for assessment of anti-tumour activity, one with microsatellite stable (MSS) mCRC had a partial response (PR) with an 86% reduction in the size of target lesions at the 26-week scan”

NCT ID

PG545 (pixatimod) in combination with nivolumab

Date Trial Added

2019-04-26

Updated Date

2019-07-29